MorphoSys
MorphoSys
MOR
XETR
67.25
EUR
0.00%
About
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant.
Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 2.9K |
| Three Month Average Volume | 40.3K |
| High Low | |
| Fifty-Two Week High | 70 EUR |
| Fifty-Two Week Low | 15.48 EUR |
| Fifty-Two Week High Date | 17 May 2024 |
| Fifty-Two Week Low Date | 21 Nov 2023 |
| Price and Volume | |
| Current Price | 67.6 EUR |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -8.61% |
| Thirteen Week Relative Price Change | -2.28% |
| Twenty-Six Week Relative Price Change | -2.97% |
| Fifty-Two Week Relative Price Change | 103.76% |
| Year-to-Date Relative Price Change | 70.91% |
| Price Change | |
| One Day Price Change | 0.07% |
| Thirteen Week Price Change | -0.59% |
| Twenty-Six Week Price Change | 3.68% |
| Five Day Price Change | 0.52% |
| Fifty-Two Week Price Change | 143.52% |
| Year-to-Date Price Change | 93.14% |
| Month-to-Date Price Change | 0.07% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.30445 EUR |
| Book Value Per Share (Most Recent Quarter) | -8.88722 EUR |
| Tangible Book Value Per Share (Last Fiscal Year) | -30.24768 EUR |
| Tangible Book Value Per Share (Most Recent Quarter) | -39.3501 EUR |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -11.85584 EUR |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 6.94431 EUR |
| Revenue Per Share (Trailing Twelve Months) | 5.1312 EUR |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | 0 EUR |
| Dividend Per Share (Trailing Twelve Months) | 0 EUR |
| Dividend Per Share (5 Year) | 0 EUR |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -5.52955 EUR |
| Excluding Extraordinary Items (Trailing Twelve Months) | -12.48146 EUR |
| Normalized (Last Fiscal Year) | -5.18602 EUR |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -5.52955 EUR |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -12.48146 EUR |
| Including Extraordinary Items (Last Fiscal Year) | -5.52955 EUR |
| Including Extraordinary Items (Trailing Twelve Months) | -12.58638 EUR |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 18.15769 EUR |
| Cash Per Share (Most Recent Quarter) | 13.60261 EUR |
| Cash Flow Per Share (Last Fiscal Year) | -5.11548 EUR |
| Cash Flow Per Share (Trailing Twelve Months) | -12.60767 EUR |
| Free Cash Flow Per Share (Trailing Twelve Months) | -8.43027 EUR |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -118 |
| Cash Flow Revenue (Trailing Twelve Months) | -164 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -251.01% |
| Pretax Margin (Last Fiscal Year) | -80.13% |
| Pretax Margin (5 Year) | -77.44% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 78.62% |
| Gross Margin (Trailing Twelve Months) | 85.74% |
| Gross Margin (5 Year) | 85.92% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -106.65% |
| Operating Margin (Trailing Twelve Months) | -239.72% |
| Operating Margin (5 Year) | -97.21% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -79.63% |
| Net Profit Margin (Trailing Twelve Months) | -249.51% |
| Net Profit Margin (5 Year) | -78.53% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -39.02% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 30.43% |
| Revenue Growth (3 Year) | 25.53% |
| Revenue Change (Trailing Twelve Months) | -18.96% |
| Revenue Per Share Growth | 23.28% |
| Revenue Growth (5 Year) | -10.08% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 3.11% |
| Total Debt (5 Year) | 414.60% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -35.20% |
| EPS Change (Trailing Twelve Months) | -451.78% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -238,675,200 |
| Net Debt (Last Fiscal Year) | -424,670,900 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 11 |
| Price to Sales (Trailing Twelve Months) | 14 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 55 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 7 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | 0.00% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 52 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 515 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 3 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -298,709,600 |
| Free Cash Flow (Trailing Twelve Months) | -303,909,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -3 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 526 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -8.58% |
| Return on Assets (Trailing Twelve Months) | -23.99% |
| Return on Assets (5 Year) | -10.25% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -183.80% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -51.00% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -9.78% |
| Return on Investment (Trailing Twelve Months) | -31.72% |
| Return on Investment (5 Year) | -11.61% |